Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Androgen Deprivation Therapy (ADT) Market by Type (Medicine, Surgery, Other, ), By Application (Hospital, Clinic, Other, ) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Androgen Deprivation Therapy (ADT) Market by Type (Medicine, Surgery, Other, ), By Application (Hospital, Clinic, Other, ) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 169954 3300 Medical Devices & Consumables 377 242 Pages 4.5 (31)
                                          

Global Androgen Deprivation Therapy (ADT) Market is expected to grow at a CAGR of XX% during the forecast period. The major factors driving the growth of this market are increasing prevalence of prostate cancer, rising awareness about prostate cancer, and increasing number of patients diagnosed with prostate cancer. The global Androgen Deprivation Therapy (ADT) market is segmented on the basis of type into medicine, surgery, and by application into hospital, clinic. The market for medicine segment is expected to grow at a CAGR of XX% during the forecast period. The major factors driving this growth are increasing prevalence of prostate cancer and rising awareness about prostate cancer. -The number of prostate cancer cases is expected to increase by about 1.5% per year, which will lead to an increased demand for ADT treatments. -The number of men diagnosed with prostate cancer is expected to increase by about 1.5% per year, which will lead to an increased demand for ADT treatments. -There are no generic versions of ADT drugs available in the market, which means that there are no substitutes and the prices are not likely to decrease in the near future. -ADT drugs have been shown to be effective in treating prostate cancer and other conditions such as benign prostatic hyperplasia (BPH).

Industry Growth Insights published a new data on “Androgen Deprivation Therapy (ADT) Market”. The research report is titled “Androgen Deprivation Therapy (ADT) Market research by Types (Medicine, Surgery, Other, ), By Applications (Hospital, Clinic, Other, ), By Players/Companies Pfizer, Astellas Pharma, Johnson & Johnson, Novartis International, Merck, Veru, Sanofi, GlaxoSmithKline, Bayer, Orion, AstraZeneca, ”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Androgen Deprivation Therapy (ADT) Market Research Report

By Type

Medicine, Surgery, Other,

By Application

Hospital, Clinic, Other,

By Companies

Pfizer, Astellas Pharma, Johnson & Johnson, Novartis International, Merck, Veru, Sanofi, GlaxoSmithKline, Bayer, Orion, AstraZeneca,

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

242

Number of Tables & Figures

170

Customization Available

Yes, the report can be customized as per your need.


Global Androgen Deprivation Therapy (ADT) Industry Outlook


Global Androgen Deprivation Therapy (ADT) Market Report Segments:

The global Androgen Deprivation Therapy (ADT) market is segmented on the basis of:

Types

Medicine, Surgery, Other,

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Clinic, Other,

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Pfizer
  2. Astellas Pharma
  3. Johnson & Johnson
  4. Novartis International
  5. Merck
  6. Veru
  7. Sanofi
  8. GlaxoSmithKline
  9. Bayer
  10. Orion
  11. AstraZeneca

Global Androgen Deprivation Therapy (ADT) Market Overview


Highlights of The Androgen Deprivation Therapy (ADT) Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Medicine
    2. Surgery
    3. Other
  1. By Application:

    1. Hospital
    2. Clinic
    3. Other
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Androgen Deprivation Therapy (ADT) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Androgen Deprivation Therapy (ADT) Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Androgen deprivation therapy (ADT) is a type of cancer treatment that uses medications to reduce the amount of testosterone in the body. This can help to slow or stop the growth of cancer cells. ADT is usually used when other treatments, such as surgery or radiation, have not worked well enough to control the tumor.

Some of the key players operating in the androgen deprivation therapy (adt) market are Pfizer, Astellas Pharma, Johnson & Johnson, Novartis International, Merck, Veru, Sanofi, GlaxoSmithKline, Bayer, Orion, AstraZeneca.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Androgen Deprivation Therapy (ADT) Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Androgen Deprivation Therapy (ADT) Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Androgen Deprivation Therapy (ADT) Market - Supply Chain
   4.5. Global Androgen Deprivation Therapy (ADT) Market Forecast
      4.5.1. Androgen Deprivation Therapy (ADT) Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Androgen Deprivation Therapy (ADT) Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Androgen Deprivation Therapy (ADT) Market Absolute $ Opportunity

5. Global Androgen Deprivation Therapy (ADT) Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Type
      5.3.1. Medicine
      5.3.2. Surgery
      5.3.3. Other
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Androgen Deprivation Therapy (ADT) Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Application
      6.3.1. Hospital
      6.3.2. Clinic
      6.3.3. Other
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Androgen Deprivation Therapy (ADT) Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Androgen Deprivation Therapy (ADT) Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Androgen Deprivation Therapy (ADT) Demand Share Forecast, 2019-2026

9. North America Androgen Deprivation Therapy (ADT) Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Application
      9.4.1. Hospital
      9.4.2. Clinic
      9.4.3. Other
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Type
      9.7.1. Medicine
      9.7.2. Surgery
      9.7.3. Other
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Androgen Deprivation Therapy (ADT) Demand Share Forecast, 2019-2026

10. Latin America Androgen Deprivation Therapy (ADT) Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Application
      10.4.1. Hospital
      10.4.2. Clinic
      10.4.3. Other
    10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Type
      10.7.1. Medicine
      10.7.2. Surgery
      10.7.3. Other
    10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Androgen Deprivation Therapy (ADT) Demand Share Forecast, 2019-2026

11. Europe Androgen Deprivation Therapy (ADT) Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Application
      11.4.1. Hospital
      11.4.2. Clinic
      11.4.3. Other
    11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Type
      11.7.1. Medicine
      11.7.2. Surgery
      1.7.3. Other
    11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Androgen Deprivation Therapy (ADT) Demand Share, 2019-2026

12. Asia Pacific Androgen Deprivation Therapy (ADT) Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Application
      12.4.1. Hospital
      12.4.2. Clinic
      12.4.3. Other
    12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Type
      12.7.1. Medicine
      12.7.2. Surgery
      12.7.3. Other
    12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Androgen Deprivation Therapy (ADT) Demand Share, 2019-2026

13. Middle East & Africa Androgen Deprivation Therapy (ADT) Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Application
      13.4.1. Hospital
      13.4.2. Clinic
      13.4.3. Other
    13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Androgen Deprivation Therapy (ADT) Market Size and Volume Forecast by Type
      13.7.1. Medicine
      13.7.2. Surgery
      13.7.3. Other
    13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Androgen Deprivation Therapy (ADT) Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Androgen Deprivation Therapy (ADT) Market: Market Share Analysis
   14.2. Androgen Deprivation Therapy (ADT) Distributors and Customers
   14.3. Androgen Deprivation Therapy (ADT) Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Pfizer
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Astellas Pharma
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Johnson & Johnson
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Novartis International
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Merck
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Veru
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Sanofi
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. GlaxoSmithKline
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Bayer
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Orion
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. AstraZeneca
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. 
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us